Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412198 · ClinicalTrials.gov registry record · Phase 1
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
A Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT06412198: Recruiting Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations, sponsored by M.D. Anderson Cancer Center.
NCT06412198 is a Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06412198, a Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Cetuximab
- DRUG Adagrasib
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 1 |
What NCT06412198 shows while recruiting
NCT06412198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cemiplimab is the first listed.
NCT06412198 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06412198 about?
NCT06412198 is a clinical study titled "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations". To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
What is the current status of trial NCT06412198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2024-08-28. Estimated completion is 2029-03-01.
What conditions does trial NCT06412198 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations.
What interventions are being tested in trial NCT06412198?
The interventions under investigation include: Cemiplimab (DRUG), Cetuximab (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06412198?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06412198 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06412198's enrollment target sits among peer trials
31 33rd of 45 higher than 12 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
-
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI